Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HISERPIA (reserpine) is an oral tablet antihypertensive agent developed by Teva, currently in pre-launch stage as a New Drug Application. Reserpine is a rauwolfia alkaloid that works as a monoamine depleter, traditionally used to treat hypertension by reducing sympathetic nervous system activity. This product represents a revival of a legacy antihypertensive class with potential utility in blood pressure management.
Pre-Launch
Pre-launch stage suggests early-phase commercial infrastructure building with limited current team size; career growth depends on successful regulatory approval and market entry.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HISERPIA represents a pre-launch career opportunity with Teva in a legacy antihypertensive space; limited current job openings reflect early developmental stage. Career trajectory depends on successful FDA approval and market penetration, with highest near-term roles in regulatory affairs, product management, and launch preparation teams.
Brand ManagerProduct Manager
Worked on HISERPIA at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.